VYNE Therapeutics Inc.
VYNE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $19,346 | $22,047 | $28,209 | $19,926 |
| Short-Term Investments | $13,354 | $17,600 | $22,063 | $41,590 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3,186 | $4,696 | $4,641 | $2,921 |
| Total Curr. Assets | $35,886 | $44,343 | $54,913 | $64,437 |
| Property Plant & Equip (Net) | $96 | $134 | $169 | $206 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $150 | $241 | $1,341 | $2,262 |
| Total NC Assets | $246 | $375 | $1,510 | $2,468 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $36,132 | $44,718 | $56,423 | $66,905 |
| Liabilities | – | – | – | – |
| Payables | $1,197 | $1,414 | $3,534 | $2,707 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1,710 | $819 | $1,836 | $2,741 |
| Total Curr. Liab. | $4,044 | $5,836 | $12,291 | $14,819 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $25 | $63 | $99 |
| Total Liabilities | $4,044 | $5,836 | $12,291 | $14,819 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3 | $2 | $2 | $1 |
| Retained Earnings | -$752,816 | -$745,536 | -$739,781 | -$731,170 |
| AOCI | $4 | -$2 | $0 | $20 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $32,088 | $38,882 | $44,132 | $52,086 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $36,132 | $44,718 | $56,423 | $66,905 |
| Net Debt | -$19,346 | -$22,047 | -$28,209 | -$19,926 |